reports
ALK modtager anbefaling om godkendelse af EURneffy® 1 mg: En nålefri a...
ALK modtager anbefaling om godkendelse af EURneffy® 1 mg: En nålefri anafylaksibehandling til børn Intern viden ALK (ALKB:DC / OMX: ALK B) har i dag annonceret, at Det Europæiske Lægemiddelagenturs komite for godkendelse af medicin til mennesker (Committee for Medicinal Products for Human Use, ‘CHMP’) har vedtaget at anbefale en godkendelse af adrenalinnæsesprayen EURneffy® 1 mg (varemærket for neffy® i EU) til akutbehandling af allergiske reaktioner (anafylaksi) forårsaget af insektstik eller -bid, fødevarer, medicinske produkter og andre allergener samt idiopatisk eller træningsinducer...
ALK receives positive recommendation for EURneffy® 1 mg: A needle-free...
ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children Inside Information ALK (ALKB:DC / OMX: ALK B) today announced that the Committee for Medicinal Products for Human Use (‘CHMP’) of the European Medicines Agency has adopted a positive opinion recommending the granting of the marketing authorisation for EURneffy® (the trade name for neffy® in the EU) to include a 1 mg nasal adrenaline spray for the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens, as wel...
ALK to present at the 44th Annual J.P. Morgan Healthcare Conference in...
ALK to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco ALK (ALKB:DC / OMX: ALK B) today announced that the company’s president & CEO, Peter Halling, is scheduled to give a company presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, 15 January 2026, at 9.45 AM PST / 12.45 PM EST / 6.45 PM CET. Representatives of the company will be available for meetings at the conference. ALK-Abelló A/S For further information, please contact: Investor Relations: Per Plotnikof, tel. , mobile Media: Maiken Riise Andersen, tel....
ALK – Finanskalender for regnskabsåret 2026
ALK – Finanskalender for regnskabsåret 2026 Finanskalender 2026 for ALK (ALKB:DC / OMX: ALK B): 23. januar 2026: Stilleperiode20. februar 2026: Offentliggørelse af årsrapport 202516. marts 2026 kl. 16.00: Ordinær generalforsamling Indkomne forslag til dagsordenen for den ordinære generalforsamling, der er modtagetaf selskabet senest den 30. januar 2026, vil blive optaget på dagsordenen(kan fremsættes på ) 7. april 2026: Stilleperiode5. maj 2026: Delårsrapport 1. kvartal (Q1) 202623. juli 2026: ...
ALK – Financial calendar for the 2026 financial year
ALK – Financial calendar for the 2026 financial year 2026 financial calendar for ALK (ALKB:DC / OMX: ALK B): 23 January 2026: Silent period 20 February 2026: Annual report 2025 16 March 2026 at 4.00 p.m.: Annual General Meeting Written requests to have specific business transacted at the AGM will be included in theagenda if received by the company on30 January 2026 at the latest(may be emailed to ) 7 April 2026: Silent period 5 May 2026: ...
Storaktionærmeddelelse
Storaktionærmeddelelse I henhold til § 30 i Lov om kapitalmarkeder skal ALK (ALKB:DC / OMX: ALK B) hermed oplyse, at Arbejdsmarkedets Tillægspension (“ATP”) har meddelt, at ATP har reduceret sin ejerandel i ALK til under 5% af aktiekapitalen (tidligere 5,0%). Meddelelsen fra ATP er vedhæftet denne selskabsmeddelelse. ALK-Abelló A/S For yderligere oplysninger kontakt venligst:Investor Relations: Per Plotnikof, tlf. 4574 7527, mobil 2261 2525Presse: Maiken Riise Andersen, tlf. 5054 1434 Om ALKALK er en global, specialiseret medicinalvirksomhed med fokus på allergi og allergisk astma. Virks...
Major shareholder announcement
Major shareholder announcement Pursuant to Section 30 of the Danish Capital Markets Act, ALK (ALKB:DC / OMX: ALK B) hereby announces that Arbejdsmarkedets Tillægspension (“ATP”) (The Danish Supplementary Labour Market Pension) has informed ALK that ATP has reduced its ownership in ALK to below 5% of the share capital (previously 5.0%). The notification (in Danish) from ATP is attached to this company release. ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, tel. , mobile Media: Maiken Riise Andersen, tel. About ALKALK is a global specialty ...
ALK udnævner Edward Jordan til ny direktør for de kommercielle aktivit...
ALK udnævner Edward Jordan til ny direktør for de kommercielle aktiviteter i Nordamerika ALK (ALKB:DC / OMX: ALK B) har i dag annonceret udnævnelsen af Edward Jordan til ny Executive Vice President (EVP) og direktør for de kommercielle aktiviteter i Nordamerika med virkning fra 5. januar 2026. Edward Jordan afløser Søren Niegel, som midlertidigt har varetaget rollen i forlængelse af beslutningen, gældende fra 1. oktober 2025, om at inkludere ALK's to centrale kommercielle regioner, Europa og Nordamerika, i selskabets topledelse (Executive Leadership Team, ELT) for yderligere at styrke eksek...
ALK appoints Edward Jordan as new EVP and head of Commercial Operation...
ALK appoints Edward Jordan as new EVP and head of Commercial Operations North America ALK (ALKB:DC / OMX: ALK B) today announced the appointment of Edward Jordan as new Executive Vice President (EVP) and head of Commercial Operations in North America as per 5 January 2026. Edward Jordan succeeds Søren Niegel who has temporarily assumed the position following the decision, effective 1 October 2025, to elevate ALK’s two key commercial regions, Europe and North America. into the Executive Leadership Team (ELT) to further strengthen the execution of ALK’s Allergy+ strategy. Edward Jordan, an A...
- ABGSC Healthcare Research
- Morten Larsen
Nine-month interim report (Q3) 2025 (unaudited) - English version only
Nine-month interim report (Q3) 2025 (unaudited) - English version only Bemærk venligst, at rapporten udelukkende forefindes på engelsk. ALK delivers 18% global organic revenue growth with operating profit up 41% in Q3 Results were better than expected, driven by a strong momentum for tablets, adrenaline autoinjectors, and SCIT/SLIT-drops. Operating profit increased as sales growth, improved gross margin, and optimisations yielded a profit margin of 28%. The full-year outlook has been upgraded. Q3 performance highlights Comparative figures for Q3 2024 are shown in brackets. Growth ra...
Nine-month interim report (Q3) 2025 (unaudited)
Nine-month interim report (Q3) 2025 (unaudited) ALK delivers 18% global organic revenue growth with operating profit up 41% in Q3 Results were better than expected, driven by a strong momentum for tablets, adrenaline autoinjectors, and SCIT/SLIT-drops. Operating profit increased as sales growth, improved gross margin, and optimisations yielded a profit margin of 28%. The full-year outlook has been upgraded. Q3 performance highlights Comparative figures for Q3 2024 are shown in brackets. Growth rates are stated in local currencies (l.c.), unless otherwise indicated. Total revenue inc...
ALK opjusterer forventningerne til 2025
ALK opjusterer forventningerne til 2025 Intern viden ALK (ALKB:DC / OMX: ALK B) har i dag annonceret, at forventningerne til helåret er blevet opjusteret på baggrund af resultaterne i tredje kvartal og udsigterne for resten af året. De ændrede forventninger afspejler primært det nuværende momentum i Europa. Omsætningen forventes nu at stige med 13-15% i lokale valutaer (mod tidligere: 12-14%) på baggrund af vækst i alle salgsregioner og i alle produktlinjer. Væksten vil primært være drevet af større volumener, da ALK forventer at behandle flere patienter med selskabets allergi-immunte...
ALK upgrades its full-year outlook
ALK upgrades its full-year outlook Inside information ALK (ALKB:DC / OMX: ALK B) today announced that the 2025 full-year financial outlook has been upgraded based on the performance in Q3 and the outlook for the remainder of the year. The changes mainly reflect the current business momentum in Europe. Revenue is now expected to grow by 13-15% in local currencies (previously: 12-14%), driven by growth in all sales regions and product lines. Growth will predominantly be attributable to higher volumes, as ALK expects to treat more patients with its allergy immunotherapy (AIT) and anaphyla...
Invitation til præsentation af ALK’s regnskab for de første ni måneder...
Invitation til præsentation af ALK’s regnskab for de første ni måneder (Q3) 2025 torsdag den 13. november 2025 ALK (ALKB.DC / OMX: ALK B) offentliggør delårsrapport for de første ni måneder (Q3) af 2025 om morgenen torsdag den 13. november 2025. ALK afholder senere samme dag kl. 13.30 en præsentation for investorer og analytikere, hvor ledelsen kommenterer på resultat og forventninger samt besvarer spørgsmål. ALK vil være repræsenteret ved Peter Halling, Adm. direktør, Claus Steensen Sølje, Finansdirektør og Per Plotnikof, IR-chef. Live audio-webcast Mødet audiocastes live på , hvor g...
Invitation to the presentation of ALK’s first nine months (Q3) 2025 re...
Invitation to the presentation of ALK’s first nine months (Q3) 2025 results on Thursday, 13 November 2025 ALK (ALKB.DC / OMX: ALK B) will publish its results for the first nine months (Q3) of 2025 in the morning on Thursday, 13 November 2025. Later on the same day, the company will host a presentation for investors and analysts at 1:30 p.m. CET, where ALK’s management will comment on the results for the first nine months and the outlook and be available for questions. ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR. ...
- ABGSC Healthcare Research
- Morten Larsen
ALK og GenSci indgår partnerskab om at udvide AIT-markedet i Kina
ALK og GenSci indgår partnerskab om at udvide AIT-markedet i Kina Intern viden GenSci tildeles eksklusive rettigheder til ALK’s AIT-produkter mod husstøvmideallergi i Kina.ALK vil være berettiget til upfront- og milepælsbetalinger på op til DKK 1,3 milliarder ud over indtægter fra levering af produkter til GenSci.Partnerskabet har også til formål at fremskynde introduktionen af en bredere portefølje i Kina.Partnerskabet forventes at understøtte indtjeningsmarginen på mellemlangt sigt, men forventes ikke at have væsentlig indvirkning på ALK’s omsætning og indtjening (EBIT) i 2025. ALK (ALK...
ALK and GenSci partner to expand the AIT market in China
ALK and GenSci partner to expand the AIT market in China Inside Information GenSci is granted exclusive rights to ALK’s house dust mite AIT products in China. ALK will be eligible for upfront and milestone payments of up to DKK 1.3 billion in addition to income from supplying GenSci with products.Partnership also aims to accelerate the introduction of a broader portfolio in China.Partnership is projected to become accretive to earnings margin in the medium term but is not expected to materially impact ALK’s revenue and earnings (EBIT) in 2025. ALK (ALKB:DC / OMX: ALK B) today announced a...
Real-world evidence supports clinical effectiveness of the neffy® nasa...
Real-world evidence supports clinical effectiveness of the neffy® nasal adrenaline spray ALK (ALKB:DC / OMX: ALK B) today announced that real-world evidence evaluating the clinical performance of the nasal adrenaline spray neffy® in US patients experiencing anaphylaxis symptoms during oral food challenge and allergen immunotherapy has been accepted for scientific publication. The findings represent the first large-scale analysis of treatment outcomes with neffy® during routine clinical practice and were accepted for publishing as a correspondence in the Annals of Allergy, Asthma and Immunol...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.